The MIT Laboratory for Financial Engineering Healthcare Finance Initiative

In this project, we combine structured finance and portfolio theory to design a new family of "megafunds" to support biomedical innovation. Over the last decade, financial markets have channeled trillions of dollars in investments to the real estate and lending markets. Structured finance facilitated this process by re-engineering loans and receivables into securities offering new profiles of risk and return to investors. We apply these principles to the areas of biomedical innovation and drug development, and propose a new type of megafund that will offer investors a set of attractive securities with unique risk/return profiles while multiplying the resources available for scientific research. The main objectives of the project are:

•To prove that it is possible to design a structured fund in which investing in science can generate statistically reliable and attractive returns.
•To detail how a megafund to support biomedical research would need to be structured in order to match researchers’ and investors’ interests.
•To define the roles that different stakeholders need to play in this market in order to achieve the objectives mentioned above.

Our ultimate goals are to offer a realistic solution to this challenge, to design a new mechanism to raise new pools of funds for science, and to prove that structured finance can play a role in finding answers to some of the problems facing humankind.

Research Publications

Fernandez, Jose-Maria, Roger M. Stein, and Andrew W. Lo, 2012, Commercializing Biomedical Research through Securitization, Nature Biotechnology 30, 964-975.
Download software FAQ

Fagnan, David, Jose-Maria Fernandez, Andrew W. Lo, and Roger M. Stein, 2013, Can Financial Engineering Cure Cancer?, American Economic Review: Papers & Proceedings 103(3), 406-411.

Fagnan, David, Austin Gromatzky, Roger M. Stein, Jose-Maria Fernandez, and Andrew W. Lo, 2013, Financing Drug Discovery for Orphan Diseases, Drug Discovery Today.
Download software

See more research publications>>>

Current Research

Parallel Discovery of Alzheimer's Therapeutics, Andrew W. Lo, Carole Ho, Jayna Cummings, and Kenneth S. Kosik

A Portfolio Approach to Translational Medicine: A Case Study of NCATS, Austin Gromatzky, Andrew W. Lo, Manita Singh, and Nora Yang

Optimal Capital Structure, Risk, and R&D Decisions: Theory and Evidence from the Pharmaceutical Industry, Richard Thakor and Andrew W. Lo

Is the FDA too Conservative?: Bayesian Decision Analysis of Clinical Trials, Vahid Montazerhodjat and Andrew W. Lo